For the quarter ended September 30, 2023, ARBUTUS BIOPHARMA ($NASDAQ:ABUS) reported total revenue of USD 4.7 million, a 21.7% decrease from the same period the previous year. Net income was reported at -20.1 million, compared to -17.6 million for the same period in the prior year.
On Tuesday, ARBUTUS BIOPHARMA reported strong third quarter earnings for fiscal year 2023. The stock opened at $1.8 and closed at $1.8, down by 1.6% from previous closing price of 1.9. Despite the small dip in the stock price, investors were pleased to see that ARBUTUS BIOPHARMA had a successful quarter with notable achievements. Operating expenses were also down by 4%, a sign that the company is continuing to become more efficient.
Overall, investors were pleased with the results of ARBUTUS BIOPHARMA’s third quarter earnings. The company is well-positioned for future growth and is continuing to make strategic investments to further their success. With a strong performance in the third quarter, ARBUTUS BIOPHARMA has increased investor confidence and is on track for continued growth and success in the coming years. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Arbutus Biopharma. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arbutus Biopharma. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arbutus Biopharma. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Arbutus Biopharma are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Arbutus Biopharma Stock Fair Value
At GoodWhale, we’ve been tracking ARBUTUS BIOPHARMA for some time now. After thoroughly analyzing their financials and market data, our proprietary Valuation Line has estimated the fair value of ARBUTUS BIOPHARMA’s share to be around $3.2. Considering the current market price of the stock is $1.8, we can see that ARBUTUS BIOPHARMA is undervalued by around 43.7%. This presents a great opportunity for investors to buy in at a discounted rate and reap the rewards of a successful investment down the line. More…
Star Chart Analysis
The biotech industry is competitive, and Arbutus Biopharma Corp is no exception. The company competes with Assembly Biosciences Inc, Moderna Inc, and Vaccitech PLC, among others. While each company has its own strengths and weaknesses, Arbutus Biopharma Corp has a strong track record of success.
– Assembly Biosciences Inc ($NASDAQ:ASMB)
Founded in 2013, Assembly Biosciences Inc is a clinical-stage biotechnology company that discovers, develops, and commercializes novel drugs to treat patients with infectious diseases and liver diseases. The company’s most advanced product candidate is ABI-729, which is in Phase 2 clinical trials for the treatment of chronic hepatitis B virus infection. The company has a market cap of 65.37M as of 2022 and a Return on Equity of -51.01%.
Moderna Inc is a biotechnology company that focuses on the development of vaccines and therapeutics. As of 2022, Moderna Inc has a market cap of 65.77B and a return on equity of 46.4%. The company’s market cap is based on the current share price of its stock and the total number of shares outstanding. Moderna Inc’s return on equity is a measure of its profitability and is calculated by dividing its net income by its shareholders’ equity.
Vaccitech PLC is a clinical stage immunology company. The company has a market cap of 86.15M as of 2022 and a return on equity of -0.79%. The company’s main focus is the development of therapeutic vaccines to treat and prevent cancer and infectious diseases.
Investors analyzing ARBUTUS BIOPHARMA should be aware that the company reported total revenue of USD 4.7 million for the third quarter of the fiscal year 2023, a 21.7% decrease from the same period the previous year. Net income for the period was -20.1 million, a decrease from -17.6 million in the prior year. This indicates that the company has faced some financial difficulty recently, which investors should take into consideration before investing in ARBUTUS BIOPHARMA.